Jon Hamilton

Jon Hamilton is a correspondent for NPR's Science Desk. Currently he focuses on neuroscience and health risks.

In 2014, Hamilton went to Liberia as part of the NPR team that covered Ebola. The team received a Peabody Award for its coverage.

Following the 2011 earthquake and tsunami in Japan, Hamilton was part of NPR's team of science reporters and editors who went to Japan to cover the crisis at the Fukushima Dai-ichi nuclear power plant.

Hamilton contributed several pieces to the Science Desk series "The Human Edge," which looked at what makes people the most versatile and powerful species on Earth. His reporting explained how humans use stories, how the highly evolved human brain is made from primitive parts, and what autism reveals about humans' social brains.

In 2009, Hamilton received the Michael E. DeBakey Journalism Award for his piece on the neuroscience behind treating autism.

Before joining NPR in 1998, Hamilton was a media fellow with the Henry J. Kaiser Family Foundation studying health policy issues. He reported on states that have improved their Medicaid programs for the poor by enrolling beneficiaries in private HMOs.

From 1995-1997, Hamilton wrote on health and medical topics as a freelance writer, after having been a medical reporter for both The Commercial Appeal and Physician's Weekly.

Hamilton graduated with honors from Oberlin College in Ohio with a Bachelor of Arts in English. As a student, he was the editor of the Oberlin Review student newspaper. He earned his master's degree in journalism from Columbia University, where he graduated with honors. During his time at Columbia, Hamilton was awarded the Baker Prize for magazine writing and earned a Sherwood traveling fellowship.

People recovering from a stroke will soon have access to a device that can help restore a disabled hand.

The Food And Drug Administration has authorized a device called IpsiHand, which uses signals from the uninjured side of a patient's brain to help rewire circuits controlling the hand, wrist and arm.

Updated June 7, 2021 at 3:11 PM ET

The Food and Drug Administration approved the drug aducanumab to treat patients with Alzheimer's disease on Monday. It is the first new drug approved by the agency for Alzheimer's disease since 2003.

A drug called aducanumab could become the first approved treatment designed to alter the course of Alzheimer's disease rather than relieve symptoms.

But it's unclear whether the Food and Drug Administration will approve the drug because of persistent questions about its effectiveness.

The FDA has a Monday deadline to make a decision on what would be the first new Alzheimer's drug in nearly two decades.

Copyright 2021 NPR. To see more, visit https://www.npr.org.

STEVE INSKEEP, HOST:

The Food and Drug Administration will decide whether to approve the first new drug for Alzheimer's disease since 2003. Scientists disagree about whether it works. NPR's Jon Hamilton reports.

A robotic arm with a sense of touch has allowed a man who is paralyzed to quickly perform tasks like pouring water from one cup into another.

The robotic arm provides tactile feedback directly to the man's brain as he uses his thoughts to control the device, a team reports Thursday in the journal Science.

Previous versions of the arm required the participant, Nathan Copeland, to guide the arm using vision alone.

An experimental device that turns thoughts into text has allowed a man who was left paralyzed by an accident to construct sentences swiftly on a computer screen.

The man was able to type with 95% accuracy just by imagining he was handwriting letters on a sheet of paper, a team reported Wednesday in the journal Nature.

William Stoehr is a prominent artist whose sister died of an overdose. Dr. Nora Volkow is the director of the National Institute on Drug Abuse at the National Institutes of Health.

Together, the artist and the scientist are on a mission to let people know that drug addiction is a disease, not a moral failing.

"Prevention and treatment and recovery can't take place until we get rid of the stigma and people are willing to seek help," Stoehr says.

An experimental drug intended for Alzheimer's patients seems to improve both language and learning in adults with Fragile X syndrome.

The drug, called BPN14770, increased cognitive scores by about 10% in 30 adult males after 12 weeks, a team reports in the journal Nature Medicine.

Copyright 2021 NPR. To see more, visit https://www.npr.org.

MARY LOUISE KELLY, HOST:

At an animal sanctuary in the Congo, several dozen Congolese schoolchildren are getting a crash course in bonobos.

These gentle, endangered apes, who resemble chimpanzees, are "our closest cousins," educator Blaise Mbwaki tells the students in French. "They have a human character, and they are Congolese."

"So if you eat a bonobo," Mbwaki says, "you are eating your cousin. It is cannibalism."

Pages